The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus project

Clinical Rheumatology

Volumn 29, Issue 2, 2010, Pages 167-174

  Leeb, Burkhard F ^a   Böttcher, Elke ^b   Brezinschek, Hans Peter ^c   Czerwenka, Christoph ^d   Herold, Manfred ^e   Hitzelhammer, Hans ^f   Mayrhofer, Franz ^g   Puchner, Rudolf ^h   Rainer, Franz ⁱ   Rintelen, Bernhard ^a   Schirmer, Michael ^e,j   Stuby, Ulrike ^k   Bröll, Hans ^b  

^a State Hospital Stockerau   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d Rheumatology EMCO Klinik   (Austria)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^f Ambulatorium Strohgasse   (Austria)

^g SKA der PV ^*  (Austria)

^h Private Office   (Austria)

ⁱ KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

^j GENERAL HOSPITAL KLAGENFURT   (Austria)

^k KEPLER UNIVERSITY HOSPITAL   (Austria)

more..

Author keywords

Initiation; Patient characteristics; TNF blockers

Indexed keywords

C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ADALIMUMAB; IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; AUSTRIA; CLINICAL DECISION MAKING; CONSENSUS; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; X RAY; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DECISION MAKING; DRUG ANTAGONISM; HOSPITALIZATION; MIDDLE AGED; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; AUSTRIA; DECISION MAKING; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING;

EID: 77949675323     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-009-1304-y     Document Type: Article

References (40)

1. M Feldman P Taylor E Paleolog FM Brennan RN Maini 1998 Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases Transplant Proc 30 8 4126 4127 10.1016/S0041-1345(98)01365-7 1:STN:280:DyaK1M%2Fot1yguw%3D%3D 9865320 Review (Pubitemid 29013179)
2. M Feldmann FM Brennan BM Foxwell PC Taylor RO Williams RN Maini 2005 Anti-TNF therapy: where have we got to in 2005? J Autoimmun 25 Suppl 26 28 10.1016/j.jaut.2005.09.006 1:CAS:528:DC%2BD2MXht1Ghs73M 16260118 Epub 2005 (Pubitemid 41728040)
3. JM Bathon RW Martin RM Fleischmann JR Tesser MH Schiff EC Keystone, et al. 2000 A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis N Engl J Med 343 22 1586 1593 10.1056/NEJM200011303432201 1:CAS:528:DC%2BD3cXovVeltLg%3D 11096165 (Pubitemid 32162981)
4. FC Breedveld MH Weisman AF Kavanaugh SB Cohen K Pavelka R van Vollenhoven, et al. 2006 The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment Arthritis Rheum 54 1 26 37 10.1002/art.21519 1:CAS:528: DC%2BD28XhsVens74%3D 16385520 (Pubitemid 43122183)
5. PE Lipsky DM van der Heijde EW St Clair DE Furst FC Breedveld JR Kalden JS Smolen, et al. 2000 Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group N Engl J Med 343 22 1594 1602 10.1056/NEJM200011303432202 1:CAS:528:DC%2BD3cXovVeltLk%3D 11096166 (Pubitemid 32162982)
6. C Antoni GG Krueger K de Vlam C Birbara A Beutler C Guzzo IMPACT 2 Trial Investigators, et al. 2005 Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial Ann Rheum Dis 64 1150 1157 10.1136/ard.2004.032268 1:CAS:528:DC%2BD2MXpslGmsrg%3D 15677701 (Pubitemid 41113349)
7. PJ Mease BS Goffe J Metz A Vanderstoep B Finck DJ Burge 2000 Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial Lancet 356 385 390 10.1016/S0140-6736(00)02530-7 1:CAS:528:DC%2BD3cXls1Cksr8%3D 10972371
8. PJ Mease DD Gladman CT Ritchlin EM Ruderman SD Steinfeld EH Choy, et al. 2005 Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial Arthritis Rheum 52 10 3279 3289 10.1002/art.21306 1:CAS:528: DC%2BD2MXhtF2msrjP 16200601 (Pubitemid 41447111)
9. J Brandt A Khariouzov J Listing H Haibel H Sorensen L Grassnickel, et al. 2003 Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis Arthritis Rheum 48 1667 1675 10.1002/art.11017 1:CAS:528:DC%2BD3sXltlSgu70%3D 12794835 (Pubitemid 36682375)
10. J Braun J Brandt J Listing A Zink R Alten W Golder, et al. 2002 Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial Lancet 359 1187 1193 10.1016/S0140-6736(02)08215-6 1:CAS:528:DC%2BD38XivVShsro%3D 11955536 (Pubitemid 34304258)
11. H Haibel M Rudwaleit HC Brandt Z Grozdanovic J Listing 2006 Kupper et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial Arthritis Rheum 54 2 678 681 10.1002/art.21563 1:CAS:528:DC%2BD28XhvFKhtr0%3D 16447247 (Pubitemid 43228648)
12. A Kavanaugh CE Antoni D Gladman S Wassenberg B Zhou A Beutler G Keenan, et al. 2006 The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year Ann Rheum Dis 65 8 1038 1043 10.1136/ard.2005.045658 1:CAS:528:DC%2BD28XosFahurk%3D 16439444 (Pubitemid 44133266)
13. PJ Mease AJ Kivitz FX Burch EL Siegel SB Cohen P Ory, et al. 2004 Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression Arthritis Rheum 50 7 2264 2272 10.1002/art.20335 1:CAS:528:DC%2BD2cXmsVansbc%3D 15248226 (Pubitemid 38924405)
14. DE Furst FC Breedveld JR Kalden JS Smolen GR Burmester P Emery EC Keystone MH Schiff PL van Riel ME Weinblatt MH Weisman 2006 Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006 Ann Rheum Dis 65 Suppl 3 iii2 iii15 10.1136/ard.2006.061937 17038465 (Pubitemid 44629094)
15. J Zochling D van der Heijde R Burgos-Vargas E Collantes JC Davis Jr B Dijkmans, et al. 2006 ASAS/EULAR recommendations for the management of ankylosing spondylitis Ann Rheum Dis 65 442 452 10.1136/ard.2005.041137 1:STN:280:DC%2BD287ktFGqsg%3D%3D 16126791
16. ML Prevoo MA Van't Hof HH Kuper MA van Leeuwen LB van de Putte PL van Riel, et al. 1995 Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis Arthritis Rheum 38 44 48 10.1002/art.1780380107 1:STN:280:DyaK2M7hvVeqtA%3D%3D 7818570
17. BF Leeb I Andel J Sautner M Bogdan A Maktari T Nothnagl B Rintelen 2005 Disease activity measurement of rheumatoid arthritis. Comparison of the SDAI and the DAS28 in daily routine Arthritis Rheum 53 1 56 61 10.1002/art.20923 15696565 (Pubitemid 40216352)
18. D Aletaha VPK Nell T Stamm M Uffmann S Pflugbeil K Machold JS Smolen 2005 Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score Arthritis Res Ther 7 R796 R806 10.1186/ar1740 1:CAS:528:DC%2BD2MXkt1CjsLY%3D 15987481
19. D van der Heijde B Dijkmans P Geusens J Sieper K DeWoody P Williamson, et al. 2005 Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT) Arthritis Rheum 52 2 582 591 10.1002/art.20852 15692973 (Pubitemid 40216323)
20. S Garrett T Jenkinson LG Kennedy H Whitelock P Gaisford A Calin 1994 A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index J Rheumatol 21 12 2286 2291 1:STN:280:DyaK2M3htl2qsQ%3D%3D 7699630
21. L Klareskog D van der Heijde JP de Jager A Gough J Kalden M Malaise TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators, et al. 2004 Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial Lancet 363 9410 675 681 10.1016/S0140-6736(04)15640-7 1:CAS:528:DC%2BD2cXhs12jur4%3D 15001324 (Pubitemid 38296553)
22. EW St Clair DM van der Heijde JS Smolen RN Maini JM Bathon P Emery, et al. 2004 Active-controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset study group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial Arthritis Rheum 50 11 3432 3443 10.1002/art.20568 1:CAS:528:DC%2BD2cXhtVOqtrvJ 15529377 (Pubitemid 39488667)
23. T Sokka T Pincus 2003 Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis Arthritis Rheum 48 2 313 318 10.1002/art.10817 1:CAS:528: DC%2BD3sXhslKksbc%3D 12571838 (Pubitemid 36277997)
24. A Zink A Strangfeld M Schneider P Herzer F Hierse M Stoyanova-Scholz S Wassenberg A Kapelle J Listing 2006 Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials Arthritis Rheum 54 11 3399 3407 10.1002/art.22193 1:CAS:528:DC%2BD28Xht12mtLnI 17075823 (Pubitemid 44737150)
25. T Pincus T Sokka CP Chung G Cawkwell 2006 Declines in number of tender and swollen joints in patients with rheumatoid arthritis seen in standard care in 1985 versus 2001: possible considerations for revision of inclusion criteria for clinical trials Ann Rheum Dis 65 7 878 883 10.1136/ard.2005.044131 1:STN:280:DC%2BD28zlsVKhtQ%3D%3D 16339290 Epub 2005 Dec 8
26. RB Hynes Dl Sacket JMA Gray GH Guyett 1996 Transferring evidence from research into practice. 1. The role of clinical care research evidence in clinical decisions Evid.-Based Med 1 196 197
27. www.Rheuma2000.at
28. MJ Elliott RN Maini M Feldmann JR Kalden C Antoni JS Smolen B Leeb FC Breedveld JD Macfarlane H Bijl, et al. 1994 Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis Lancet 344 8930 1105 10 10.1016/S0140-6736(94) 90628-9 1:STN:280:DyaK2M%2FitVWktw%3D%3D 7934491 (Pubitemid 24317629)
29. X Baraliakos J Listing M Rudwaleit J Brandt J Sieper J Braun 2005 Radiographic progression in patients with ankylosing spondylitis after two years of treatment with the tumor necrosis factor-a antibody infliximab Ann Rheum Dis 64 1462 1666 10.1136/ard.2004.033472 1:STN:280:DC%2BD2MvptFCjsw%3D%3D 15778240 (Pubitemid 41623858)
30. EC Keystone AF Kavanaugh JT Sharp H Tannenbaum Y Hua LS Teoh, et al. 2004 Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial Arthritis Rheum 50 5 1400 1401 10.1002/art.20217 1:CAS:528:DC%2BD2cXkvFykur4%3D 15146409 (Pubitemid 38608061)
31. T Pincus JA Summey SA Soraci Jr KA Wallston NP Hummon 1983 Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire Arthritis Rheum 26 1346 1353 10.1002/art.1780261107 1:STN:280:DyaL2c%2Flt1Khsg%3D%3D 6639693
32. F Wolfe 2000 A reappraisal of HAQ disability in rheumatoid arthritis Arthritis Rheum 43 12 2751 2761 10.1002/1529-0131(200012)43:12<2751::AID- ANR15>3.0.CO;2-6 1:STN:280:DC%2BD3M%2FnvFymtQ%3D%3D 11145033 (Pubitemid 32001741)
33. T Pincus OG Segurado 2006 Most visits of most patients with rheumatoid arthritis to most rheumatologists do not include a formal quantitative joint count Ann Rheum Dis 65 6 820 822 10.1136/ard.2005.044230 1:STN:280: DC%2BD283mslCmsQ%3D%3D 16291813 (Pubitemid 43799185)
34. BF Leeb PM Haindl A Maktari T Nothnagl B Rintelen 2008 Patient-centered rheumatoid arthritis disease activity assessment by a modified RADAI J Rheumatol 35 7 1294 1299 18484698
35. T Pincus Y Yazici M Bergman R Maclean T Harrington 2007 A proposed continuous quality improvement approach to assessment and management of patients with rheumatoid arthritis without formal joint counts based on quantitative routine assessment of patient index data (RAPID) scores on a multidimensional health assessment questionnaire (MDHAQ) Best Pract Res Clin Rheumatol 21 4 789 804 10.1016/j.berh.2007.02.009 17678835 (Pubitemid 47177167)
36. C Salvarani F Cantini I Olivieri P Macchioni A Padula L Niccoli, et al. 2003 Efficacy of infliximab in resistant psoriatic arthritis Arthritis Rheum 49 4 541 545 10.1002/art.11201 1:CAS:528:DC%2BD3sXntVClt7Y%3D 12910561
37. S Gérard B le Goff Y Maugars JM Berthelot 2008 Six-month response to anti-TNF drugs in axial spondylarthropathy according to the fulfillment or not of New-York criteria for ankylosing spondylitis or French recommendations for anti-TNF use. A "real life" retrospective study on 175 patients Jt Bone Spine 75 6 680 687 10.1016/j.jbspin.2008.03.006
38. B Zhang M Lavalley DT Felson 2009 The sensitivity to change for lower disease activity is greater than for higher disease activity in rheumatoid arthritis trials Ann Rheum Dis 68 1255 1259 10.1136/ard.2008.092460 1:STN:280:DC%2BD1MvosF2lsw%3D%3D 18697778
39. BF Leeb J Sautner BA Leeb C Fassl B Rintelen 2006 Lack of agreement between patients' and physicians' perspectives of rheumatoid arthritis disease activity changes Scand J Rheumatol 35 6 441 446 10.1080/03009740600906727 1:STN:280:DC%2BD2s7ktlyjsA%3D%3D 17343251 (Pubitemid 47215711)
40. T Pincus Y Yazici MJ Bergman 2008 Quantitative rheumatology. Hotel-based medicine J Rheumatol 35 1487 1489 10.3899/jrheum.080182 18671322